1Malfertheiner P, Megraud F, O'Morain C, et al. Current conceptsin the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus reports. Aliment Pharmacol Ther, 2002,16:167-180.
2Warren JR. Gastric pathology associated with Helicobacter pylori.Gastroenterol Clin North Am, 2000,29:705-751.
3Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment fornon-ulcer dyspepsia. BMJ, 2000,321:659-664.
4Talley NJ, Meineche-Schmit V, PareP, etal. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebocontrolledtrials. Aliment Pharmacol Ther, 1998,12:1055-1065.
5Sung J J, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasis one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology,2000,119: 7-14.
6Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a5-year prospective study of patients with atrophic gastritis. AlimentPharmacol Ther,2002,16:1449-1456.
7Hsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacterpylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther, 2001,15:195-201.
8Sheu BS, Yang HB, Wang YL, et al. Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylorieradication in patients with nonulcer dyspepsia. Dig Dis Sci,2001,46;2700-2707.
